Country: Танзанија
Језик: Енглески
Извор: Tanzania Medicinces & Medical Devices Authority
Mycophenolate mofetil
Intas Pharmaceuticals Limited, INDIA
Cytoxic antibiotics
Mycophenolate mofetil
500
Film coated tablets
Intas Pharmaceuticals Limited, INDIA
Physical description: Purple coloured, oval shaped, biconvex, film coated tablets; Local technical representative: PHARMAJEN LIMITED (61840)
Registered/Compliant
2020-12-24
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Mphetas-500 (Mycophenolate Mofetil Tablets USP 500 mg) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film coated tablet contains Mycophenolate Mofetil USP 500 mg See List of Excipients in section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet Purple coloured, oval shaped, biconvex, film coated tablets. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Mycophenolate mofetil 500mg Tablets are indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Treatment with Mycophenolate mofetil 500mg Tablets should be initiated and maintained by appropriately qualified transplant specialists. Posology _Use in renal transplant _ _Adults_ _ _ Oral Mycophenolate mofetil 500mg Tablets should be initiated within 72 hours following transplantation. The recommended dose in renal transplant patients is 1g administered twice daily (2g daily dose). _Paediatric population aged 2 to 18 years_ _ _ The recommended dose of mycophenolate mofetil is 600mg/m2 administered orally twice daily (up to a maximum of 2g daily). Mycophenolate mofetil 500mg Tablets should only be prescribed to patients with a body surface area greater than 1.5 m2, at a dose of 1g twice daily (2g daily dose). As some adverse reactions occur with greater frequency in this age group (see section 4.8) compared with adults, temporary dose reduction or interruption may be required; these will need to take into account relevant clinical factors including severity of reaction. _Paediatric population < 2 years_ _ _ There are limited safety and efficacy data in children below the age of 2 years. These are insufficient to make dosage recommendations and therefore use in this age group is not recommended. _Use in cardiac transplant Adults_ _ _ Oral Mycophenolate mofetil 500mg Tablets should be initiated within 5 days following transplantation Прочитајте комплетан документ